Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $59.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.19M
Average 0.43M
Returns on capital
Fortress Biotech, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
13.7%
avg -529.3%
ROIC
-50.0%
avg -80.8%
ROA
3.7%
avg -27.4%
Analysis
ROE is currently the strongest return metric at 13.7% versus its period average of -529.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Lindsay Allan Rosenwald | Executive Chairman, President & Chief Executive Officer | USD 687.67K | 71 | — | — |
David Jin | Chief Financial Officer & Head of Corporate Development | USD 664.08K | 36 | 1.65M | 4.98% |
Michael S. Weiss | Executive Vice Chairman of Strategic Development & Director | USD 652.67K | 60 | 2.28M | 6.85% |
Xiaoqin Lu | Chief Strategy Officer | USD 15K | 51 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -5.8% | +40.4% (2yr)1 analysts |
| Net Income | N/A | N/A | N/A | +89.6% (2yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -5.8% over three years. Forward estimates point to Net Income at +89.6% (2yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Fortress Biotech, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about FBIO's management, answered from reported figures.
Who manages FBIO?
Fortress Biotech, Inc. (FBIO) lists 4 active executives. The top listed executive is Xiaoqin Lu, Chief Strategy Officer.
Are FBIO insiders buying or selling?
Recent insider activity shows net buying of $16.69M.
Continue the stock analysis
Jump to another research area for this company.